Hepatitis C transmission from seropositive, nonviremic donors to non–hepatitis C liver transplant recipients

Khurram Bari, Keith Luckett, Tiffany Kaiser, Tayyab Diwan, Madison Cuffy, Michael R. Schoech, Kamran Safdar, Jason T. Blackard, Senu Apewokin, Flavio Paterno, Kenneth E. Sherman, Stephen D. Zucker, Nadeem Anwar, Shimul A. Shah – 2 December 2017 – Breakthroughs in hepatitis C virus (HCV) treatment and rising rates of intravenous drug use have led to an increase in the number of organ donors who are HCV antibody–positive but serum nucleic acid test (NAT)–negative. The risk of HCV transmission from the liver grafts of these donors to recipients is unknown.

Reply

Behnam Saberi, Alia S. Dadabhai, Christine M. Durand, Benjamin Philosophe, Andrew M. Cameron, Mark S. Sulkowski, Ahmet Gurakar – 2 December 2017

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience

Riad Salem, Ahmed Gabr, Ahsun Riaz, Ronald Mora, Rehan Ali, Michael Abecassis, Ryan Hickey, Laura Kulik, Daniel Ganger, Steven Flamm, Rohi Atassi, Bassel Atassi, Kent Sato, Al B. Benson, Mary F. Mulcahy, Nadine Abouchaleh, Ali Al Asadi, Kush Desai, Bartley Thornburg, Michael Vouche, Ali Habib, Juan Caicedo, Frank H. Miller, Vahid Yaghmai, Joseph R. Kallini, Samdeep Mouli, Robert J. Lewandowski – 1 December 2017 – Yttrium‐90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for hepatocellular carcinoma (HCC).

Subscribe to